Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neo-Sequence 2:NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.
Official title: Neo-Sequence 2:Phase 2 Study of Neoadjuvant Chemotherapy Plus Anti-angiogenesis Therapy and Immunotherapy for Locally Advanced Diffuse Gastric Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
67
Start Date
2024-03-01
Completion Date
2027-03-01
Last Updated
2024-04-17
Healthy Volunteers
No
Conditions
Interventions
Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy
Albumin paclitaxel+SOX+BEV bi weekly neoadjuvant therapy for 6 cycles, with PD-1 monoclonal antibody therapy interspersed for 4 cycles. Review CT and gastroscopy every 3 cycles to evaluate the therapeutic effect. Patients who have been evaluated as effective after 6 cycles of treatment may consider surgery; Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles. Afterwards, the therapeutic effect will be evaluated, and surgery, radiotherapy, or maintenance medication treatment will be determined based on the therapeutic effect. Surgical patients begin adjuvant treatment 1-2 months after surgery based on the curative and pathological results of the surgery. Those who fail to evaluate during neoadjuvant therapy will undergo surgery or radiation therapy, or switch to a second-line systemic treatment plan.
Locations (1)
Cancer hospital,Chinese acadamy of medical sciences
Beijing, China